Led · Series A · Mar 2026

Blue Arbor Technologies focuses on next-generation neuromuscular interfaces that directly connect residual muscles and peripheral nerves to advanced robotic prostheses. Its flagship RESTORE Neuromuscular Interface System, which has FDA Breakthrough Device Designation and entry into the FDA’s Total Product Life Cycle Advisory Program Pilot, enables independent, simultaneous control of fingers, wrist, and elbow via a wireless sensing unit. Early feasibility studies show the system can capture stable, high-quality motor signals for more than five years, and the first-in-human implantation performed in December 2025 quickly produced functional, natural movement. The technology stems from nearly two decades of academic research led by the founders, whose work has attracted over $60 million in grant funding and generated 200+ peer-reviewed publications. Blue Arbor plans to use its new capital and strategic partnership with Ottobock to accelerate clinical trials, expand product development, and prepare for commercial launch. Financially, the company has now begun its Series A raise with a $5 million anchor investment, but RESTORE remains an investigational device not yet cleared for sale.

Participated · Equity · Oct 2025

Onward commercializes ARC Therapy, a suite of neurostimulation technologies founded on research from CHUV and UNIL by Grégoire Courtine, Jocelyne Bloch, and Vincent Delattre. Its ARC-EX® system is already cleared for use in the United States and Europe, positioning the company as a commercial-stage player. The implantable ARC-IM® platform is in clinical evaluation, including studies targeting blood pressure instability in spinal cord injury patients. Onward recently raised more than €40 million, including €25 million from EQT Life Sciences, which extends its financial runway into early 2028. The company plans to use the new capital to accelerate product development, expand commercial activities in key markets, and support further clinical validation and regulatory work.

Led · Series A · Apr 2025

Phantom Neuro develops a minimally invasive neural interface platform called Phantom X to enable intuitive control of prosthetic limbs and robotic exoskeletons. Phantom X, originally developed at the Johns Hopkins University School of Medicine, is designed to restore natural movement by making assistive devices function as seamless extensions of the body. The company reported that its ASCENT study demonstrated 94% accuracy decoding real-time gestures across 11 essential hand and wrist movements. Phantom Neuro has received FDA Breakthrough Device and TAP designations for Phantom X, which may expedite regulatory approvals. The company plans to use new funding to accelerate preclinical testing, complete first-in-human trials, pursue regulatory submissions, and expand R&D for broader control applications beyond prosthetic limbs. Phantom Neuro is headquartered in Austin, Texas and has raised $28 million in total funding to date. Phantom Neuro develops a low-power, high-accuracy system intended to provide lifelike control of robotic orthopedic technologies. The company is positioned in the neurotech sector and is based in Austin, TX. Its core product targets control interfaces for robotic orthopedics, emphasizing low power consumption and high accuracy. The article does not disclose operating metrics such as revenue or user counts. Phantom Neuro announced a $6 million expanded seed financing, which increases its total funding to $9.5 million. The funding supports the company’s continued development of its control system for robotic orthopedic applications. Phantom Neuro is a neurotechnology company based in Austin, Texas and Baltimore, Maryland that is creating a system to enable lifelike control of robotic orthopedic technologies such as prosthetic limbs and exoskeletons. Its solution combines low-risk implantable sensors, AI, and enabling software to provide control of existing and next-generation orthopedic devices. The company is led by founder and CEO Dr. Connor Glass. Phantom Neuro raised seed funding to expand its operations and business reach. The $3.26M round was led by LionBird Ventures with participation from Draper Associates, Breakout Ventures, Blackrock Neurotech, Capital Factory, and private investors. As part of the financing, LionBird partner Robert Lord will join the board and LionBird Managing Partner Ed Michael will join as a board observer.